


What is claimed is:

1. A compound of the formula IA-IF having the following structure:



IA-IF

wherein:

the carbon atom designated \* is in the R or S configuration;

R<sup>1</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted with 1 to 3 substituents independently selected at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>;

R<sup>2</sup> is H, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl;

R<sup>3</sup> is H, halogen, -OR<sup>11</sup>, -S(O)<sub>0</sub>R<sup>12</sup>, -S(O)<sub>0</sub>NR<sup>11</sup>R<sup>12</sup>, -CN, -C(O)R<sup>12</sup>, -C(O)NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -O(phenyl) or -O(benzyl), wherein each of -O(phenyl) and -O(benzyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy, or wherein R<sup>3</sup> is a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>; provided that for compounds of formula IA, R<sup>3</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>;

provided that for compounds of formula IB,  $R^3$  is  $-O(\text{phenyl})$ ,  $-O(\text{benzyl})$ ,  $-OC(O)R^{13}$  or  $-S(O)_nR^{12}$ , each of  $-O(\text{phenyl})$  and  $-O(\text{benzyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  alkoxy;

5  $R^4$  is H, halogen,  $-OR^{11}$ ,  $-S(O)_nR^{12}$ ,  $-S(O)NR^{11}R^{12}$ ,  $-CN$ ,  $-C(O)R^{12}$ ,  $-C(O)NR^{11}R^{12}$ ,  $-NR^{11}R^{12}$ ,  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_3-C_6$  cycloalkyl,  $C_4-C_7$  cycloalkylalkyl,  $-O(\text{phenyl})$  or  $-O(\text{benzyl})$ , wherein each of  $-O(\text{phenyl})$  and  $-O(\text{benzyl})$  is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  alkoxy and wherein  $R^4$  is a  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_3-C_6$  cycloalkyl or  $C_4-C_7$

10 cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1-C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$ ; provided that for compounds of formula IC,  $R^4$  is  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_3-C_6$  cycloalkyl, or  $C_4-C_7$  cycloalkylalkyl, each of which is optionally substituted;

15 provided that for compounds of formula ID,  $R^4$  is  $-O(\text{phenyl})$ ,  $-O(\text{benzyl})$ ,  $-OC(O)R^{13}$ ,  $-NR^{11}R^{12}$  or  $-S(O)_nR^{12}$ , each of  $-O(\text{phenyl})$  and  $-O(\text{benzyl})$  being optionally substituted;

$R^5$ ,  $R^6$  and  $R^7$  in compounds of each of the formulae IA, IB, IC, ID, IE and IF are each independently H, halogen,  $-OR^{11}$ ,  $-S(O)_nR^{12}$ ,  $-CN$ ,  $-C(O)R^{12}$ ,  $-NR^{11}R^{12}$ ,  $-C(O)NR^{11}R^{12}$ ,  $-NR^{11}C(O)R^{12}$ ,  $-NR^{11}C(O)_2R^{12}$ ,  $-NR^{11}C(O)NR^{12}R^{13}$ ,  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_3-C_6$  cycloalkyl or  $C_4-C_7$  cycloalkylalkyl, wherein each of  $R^5$ ,  $R^6$  and  $R^7$  is a  $C_1-C_6$  alkyl,  $C_2-C_6$  alkenyl,  $C_2-C_6$  alkynyl,  $C_3-C_6$  cycloalkyl or  $C_4-C_7$  cycloalkylalkyl group, then said group is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1-C_3$  alkyl, halogen, aryl,  $-CN$ ,  $-OR^9$  and  $-NR^9R^{10}$ , or  $R^5$  and  $R^6$  or  $R^6$  and  $R^7$  may be  $-O-C(R^{12})_2-O-$ ;

20 provided that for compounds of formula IE at least one of  $R^5$  or  $R^7$  is fluoro, chloro, or methyl; or  $R^5$  and  $R^6$  are each independently  $-O-C(R^{12})_2-O-$  in compounds of the formulae IE, but only where  $R^7$  is fluoro, chloro or methyl;

25 or  $R^7$  and  $R^6$  can independently also be  $-O-C(R^{12})_2-O-$  in compounds of the formulae IE, but only where  $R^5$  is fluoro, chloro or methyl;

$R^8$  is H, halogen, or  $OR^{11}$ , provided that for compounds of formula IF,  $R^8$  is halogen;

30  $R^9$  and  $R^{10}$  are each independently H,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl,  $C_1-C_4$  alkoxyalkyl,  $C_3-C_6$  cycloalkyl,  $C_4-C_7$  cycloalkylalkyl,  $-C(O)R^{13}$ , phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1-C_4$  alkyl,  $C_1-C_4$  haloalkyl, or  $C_1-C_4$  alkoxy;

or  $R^9$  and  $R^{10}$  are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;

~~R<sup>11</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, -C(O)R<sup>13</sup>, phenyl or benzyl, where R<sup>11</sup> is a C<sub>1</sub>-C<sub>4</sub> alkyl, phenyl or benzyl group, then said group is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy;~~

~~5 R<sup>12</sup> is H, amino, C<sub>1</sub>-C<sub>4</sub> alkyl, (C<sub>1</sub>-C<sub>4</sub> alkyl)amino, C<sub>1</sub>-C<sub>4</sub> haloalkyl, C<sub>1</sub>-C<sub>4</sub> alkoxyalkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, phenyl or benzyl, where phenyl or benzyl is optionally substituted from 1 to 3 times with a substituent selected independently from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy;~~

~~or R<sup>11</sup> and R<sup>12</sup> are taken together with the nitrogen to which they are attached to form piperidine,~~

~~10 pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;~~

~~provided that only one of R<sup>9</sup> and R<sup>10</sup> or R<sup>9</sup> and R<sup>10</sup> are taken together with the nitrogen to which they are attached to form piperidine, pyrrolidine, piperazine, N-methylpiperazine, morpholine, or thiomorpholine;~~

~~R<sup>13</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl or phenyl;~~

~~n is 0, 1, or 2, and;~~

~~15 aryl is phenyl which is optionally substituted 1-3 times with halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl and C<sub>1</sub>-C<sub>4</sub> alkoxy, or~~

~~an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or prodrug thereof.~~

2. The compound of claim 1, wherein R<sup>1</sup> is C<sub>1</sub>-C<sub>3</sub> alkyl.

3. The compound of claim 2, wherein R<sup>1</sup> is CH<sub>3</sub>.

4. The compound of claim 1, wherein R<sup>2</sup> is H, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>6</sub> haloalkyl.

5. The compound of claim 4, wherein R<sup>2</sup> is H or CH<sub>3</sub>.

6. The compound of claim 1, wherein R<sup>3</sup> is H or R<sup>3</sup> is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from C<sub>1</sub>-C<sub>3</sub> alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>, or R<sup>3</sup> is -O(phenyl) or -O(benzyl) optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy.

7. The compound of claim 6, wherein R<sup>3</sup> is methyl, ethyl, propyl, or isopropyl.

8. The compound of claim 6, wherein  $R^3$  is -O(phenyl) or -O-CH<sub>2</sub>-(phenyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy.

5 9. The compound of claim 6, wherein  $R^3$  is H.

10. The compound of claim 1, wherein  $R^4$  is H, or  $R^4$  is -NR<sup>11</sup>R<sup>12</sup> or  $R^4$  is C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl or C<sub>4</sub>-C<sub>7</sub> cycloalkylalkyl, each of which is optionally substituted, or wherein  $R^4$  is -O(phenyl) or -O(benzyl), each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy.

11. The compound of claim 10, wherein  $R^4$  is methyl, ethyl, propyl, or isopropyl.

15 12. The compound of claim 10, wherein  $R^4$  is -O(phenyl) or -O(CH<sub>2</sub>)phenyl, each of which is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> haloalkyl, or C<sub>1</sub>-C<sub>4</sub> alkoxy.

13. The compound of claim ~~10~~, wherein  $R^4$  is H.

14. The compound of claim 1, wherein  $R^3$  and  $R^4$  are each H or wherein  $R^3$  and  $R^4$  are each halogen.

15. The compound of claim 1, wherein one of  $R^3$  and  $R^4$  is H and the other is CH<sub>3</sub>.

25 16. The compound of claim 1, wherein  $R^5$ ,  $R^6$  and  $R^7$  are each H, halogen, -OR<sup>11</sup>, -NR<sup>11</sup>R<sup>12</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl and substituted C<sub>1</sub>-C<sub>6</sub> alkyl.

17. The compound of claim 16, wherein  $R^5$ ,  $R^6$  and  $R^7$  are each H.

30 18. The compound of claim 16, wherein one of  $R^5$  or  $R^7$  is F, Cl or Me and the other of  $R^5$  or  $R^7$  and  $R^6$  are H, halogen, -OR<sup>11</sup>, -NR<sup>11</sup>R<sup>12</sup>, or optionally substituted C<sub>1</sub>-C<sub>6</sub> alkyl.

19. The compound of claim 18, wherein  $R^5$  is F, Cl or Me; and  $R^7$  is H.

20. The compound of claim 18, wherein  $R^5$  is F, Cl or Me; and  $R^6$  is H.

21. The compound of claim 1, wherein  $R^8$  is halogen.

22. The compound of claim 21, wherein  $R^8$  is fluoro.

23. The compound of claim 1, wherein:

$R^1$  is  $C_1$ - $C_3$  alkyl;

$R^2$  is H,  $C_1$ - $C_4$  alkyl or  $C_1$ - $C_6$  haloalkyl;

$R^3$  is  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted, or  $R^3$  is -O(phenyl) or -O(benzyl), each of which is optionally substituted, or  $R^3$  is H;  $R^4$  is H,  $C_1$ - $C_4$  alkyl,  $C_3$ - $C_6$  cycloalkyl or  $C_4$ - $C_7$  cycloalkylalkyl, each of which is optionally substituted with from 1 to 3 substituents selected independently at each occurrence thereof from  $C_1$ - $C_3$  alkyl, halogen, aryl, -CN, -OR<sup>9</sup> and -NR<sup>9</sup>R<sup>10</sup>, or  $R^4$  is -NR<sup>11</sup>R<sup>12</sup>, -O(phenyl) or -O(benzyl), wherein said -O(phenyl) or -O(benzyl), is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

or  $R^3$  and  $R^4$  are each halogen;

$R^5$ ,  $R^6$  and  $R^7$  are each H, halogen, -OR<sup>11</sup>, -NR<sup>11</sup>R<sup>12</sup>, optionally substituted  $C_1$ - $C_6$  alkyl, or one of  $R^5$  and  $R^7$  is Cl, F or Me and the other of  $R^5$  and  $R^7$  and  $R^6$  is H, halogen, -OR<sup>11</sup>, -NR<sup>11</sup>R<sup>12</sup>,  $C_1$ - $C_6$  alkyl or substituted  $C_1$ - $C_6$  alkyl.

24. The compound of claim 23, wherein:

$R^1$  is CH<sub>3</sub>;

$R^2$  is H or CH<sub>3</sub>;

$R^3$  is H, F, methyl, ethyl, propyl, isopropyl, -O(phenyl) or -O-CH<sub>2</sub>-(phenyl), wherein said -O(phenyl) or -O-CH<sub>2</sub>-(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

$R^4$  is H, F methyl, ethyl, propyl, isopropyl, -O(phenyl) or -O-CH<sub>2</sub>-(phenyl), wherein said -O(phenyl) or -O-CH<sub>2</sub>-(phenyl) is optionally substituted from 1 to 3 times with a substituent selected independently at each occurrence thereof from halogen, cyano,  $C_1$ - $C_4$  alkyl,  $C_1$ - $C_4$  haloalkyl, or  $C_1$ - $C_4$  alkoxy;

$R^5$ ,  $R^6$  and  $R^7$  are each H or  $R^5$  is F, Cl or Me, or one of  $R^6$  or  $R^7$  is H and the other of  $R^6$  and  $R^7$  is halogen,  $-OR^{11}$ ,  $-NR^{11}R^{12}$ , or optionally substituted  $C_1-C_6$  alkyl.

25. The compound of claim 23, wherein  $R^8$  is halogen.

26. A compound according to claim 1, wherein the carbon atom designated \* is in the R configuration.

27. A compound according to claim 1, wherein the carbon atom designated \* is in the S configuration.

28. A composition comprising a mixture of stereoisomeric compounds of claim 1 wherein the carbon atom designated \* is in the S or R configuration.

29. A radiolabelled compound of claim 1.

30. A compound according to claim 1, selected from the group:

2,7-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-methoxy)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro-4-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

2,7-dimethyl-4-(3-fluoro-4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(4-chloro-3-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-dichloro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;

7-ethyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

4-(3,4-difluoro)phenyl-7-ethyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(3-fluoro-4-methoxy)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

7-fluoro-4-(3-fluoro-4-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

at 5  
con

00207T " 90E40260

- 7-fluoro-4-(4-chloro-3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,4-difluoro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro)phenyl-7-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 7-cyano-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-4-phenyl-7-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-chloro)phenyl-1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,4-difluoro)phenyl-1,2-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-phenyl-2,7,8-trifluoromethyl-1,2,3,4-tetrahydroisoquinoline;  
 10 2,7-dimethyl-8-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-7-fluoro-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,7-dimethyl-8-methoxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,7-dimethyl-8-hydroxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-4-phenyl-7-trifluoromethoxy-1,2,3,4-tetrahydroisoquinoline;  
 15 4-(3,4-difluoro)phenyl-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-fluoro-3-methyl)phenyl-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-fluoro-4-methyl)phenyl-7-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 7-methoxy-4-(3-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-7-phenoxy-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 20 7-(4-methoxy)phenoxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 7-benzyloxy-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 7-hydroxy-2-methyl-4-(3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-fluoro-4-methyl)phenyl-7-hydroxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-fluoro-3-methyl)phenyl-7-hydroxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 25 4-(3,4-difluoro)phenyl-7-hydroxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-cyano)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,4-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 30 4-(3,5-difluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(3-fluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-fluoro-3-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro-4-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,4-dichloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 35 4-(3-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;

5

4-(4-chloro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-chloro-3-fluoro)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-methoxy)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-cyano)phenyl-2,8-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-trifluoromethyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2,8-dimethyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-8-(N-methylamino)methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 8-(hydroxy)methyl-2-methyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-4-phenyl-8-sulfonamide-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-8-(N-methyl)sulfonamide-4-phenyl-1,2,3,4-tetrahydroisoquinoline;

10

8-methoxy-2-methyl-4-(4-methyl)phenyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,5-difluoro)phenyl-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro)phenyl-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,4-dichloro)phenyl-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-chloro-3-fluoro)phenyl-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro-4-fluoro)phenyl-8-methoxy-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,5-difluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro-5-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,5-difluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro-5-fluoro)phenyl-2,7-dimethyl-1,2,3,4-tetrahydroisoquinoline;  
 2-methyl-4-(3,4,5-trifluoro)phenyl-1,2,3,4-tetrahydroisoquinoline;

15

20

4-(3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-fluoro-4-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-fluoro-3-methyl)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3,4-difluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-chloro-3-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-chloro-4-fluoro)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(3-cyano)phenyl-2-methyl-1,2,3,4-tetrahydroisoquinoline;

25

30

4-(4-acetanilide)-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 4-(4-chloro)phenyl-4-fluoro-2-methyl-1,2,3,4-tetrahydroisoquinoline;  
 (3,5-difluoro)-4-phenyl-1,2,7-trimethyl-1,2,3,4-tetrahydroisoquinoline;  
 (8-fluoro-2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)-N-methylmethanamine;  
 (2-methyl-4-phenyl-7-isoquinoliny)-N-methylmethanamine;  
 N-methyl(2-methyl-4-phenyl-7-isoquinoliny)-N-methylmethanamine;

35



8-hydroxy-2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinolinecarbonitrile;  
 (2-methyl-4-phenyl-1,2,3,4-tetrahydro-7-isoquinoliny)l)methanol; and  
 2-ethyl-4-phenyl-1,2,3,4-tetrahydroisoquinoline; and  
 an oxide thereof, a pharmaceutically acceptable salt thereof, a solvate thereof, or prodrug thereof.

31. A compound according to claim 1, selected from table C.

32. A compound according to claim 1, wherein the enantiomer is selected from table D.

33. A compound according to claim 30, which is the (+) stereoisomer.

34. A compound according to claim 30, which is the (-) stereoisomer.

35. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of claim 1.

36. A method of treating a disorder which is created by or is dependent upon decreased availability of serotonin, norepinephrine or dopamine, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

37. A method according to claim 36, which further comprises administering a therapeutically effective amount of a serotonin 1A receptor antagonist, or pharmaceutically acceptable salt thereof.

38. A method according to claim 37 wherein the serotonin 1A receptor antagonist is chosen from the group consisting of WAY 100135 and spiperone.

39. A method according to claim 36, which further comprises administering a therapeutically effective amount of a selective neurokinin-1 receptor antagonist, or pharmaceutically acceptable salt thereof.

40. A method according to claim 36, which further comprises administering a therapeutically effective amount of a norepinephrine precursor, or pharmaceutically acceptable salt thereof.

41. A method according to claim 40, wherein the norepinephrine precursor is selected from the group consisting of L-tyrosine and L-phenylalanine.

42. A method according to claim 36, wherein the disorder is selected from the group: attention deficit disorder, hyperactivity disorder, anxiety, depression, post-traumatic stress disorder, supranuclear palsy, eating disorders, obsessive compulsive disorder, analgesia, nicotine addiction, panic attacks, Parkinsonism and phobia, obesity, late luteal phase syndrome or narcolepsy, cocaine addiction, amphetamine addiction, and psychiatric symptoms anger such as, rejection sensitivity, and lack of mental or physical energy.

10

43. A method of inhibiting synaptic norepinephrine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 1.

44. A method of inhibiting synaptic serotonin uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 1.

45. A method of inhibiting synaptic dopamine uptake in a patient in need thereof comprising administering a therapeutically effective inhibitory amount of a compound according to claim 1.

46. The method of claim 36 wherein the (+)-stereoisomer of the compound is employed.

47. The method of claim 36 wherein the (-)-stereoisomer of the compound is employed.

48. A kit comprising a compound according to claim 1 and at least one compound selected from the group consisting of: a serotonin 1A receptor antagonist compound, a selective neurokinin-1 receptor antagonist compound, and a norepinephrine precursor compound.

49. The method of claim 36 for treating attention deficit/hyperactivity disorder.

002011" 90240260

add  
a'